Tag : ASCVD

CONFERENCE UPDATE

Triglyceride reduction with olezarsen in HTG patients with high CV risk: The BRIDGE-TIMI 73a trial
CONFERENCE UPDATE

“Inclisiran first” strategy lowers LDL-C in real-world ASCVD patients: Results from the VICTORION-INITIATE trial
A reduction in LDL-C is associated with improvements in CV outcomes in patients with ASCVD.1 As such, multiple guidelines recommend LDL-C targets of <55mg/dL and <70mg/dL based on baseline risks. However, many patients fail their LDL-C goals due to clinical inertia, medication nonadherence, side effects, and/or poor healthcare access. Inclisiran is a first-in-class siRNA that inhibits hepatic PCSK9 production and increases LDL receptor expression and LDL-C clearance. In clinical studies, twice-yearly administration of inclisiran has been shown to achieve a 50% reduction in LDL-C.